[Impulse control disorder induced by the use of dopamine agonists].
Weber
Wim E J
WE
Maastricht Universitair Medisch Centrum, Afd. Neurologie, Maastricht. wim.weber@mumc.nl
Nijssen
Peter C G
PC
D052160:Benzothiazoles / Q000009:adverse effects / Q000627:therapeutic use; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced*; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use; D000077487:Pramipexole; D012148:Restless Legs Syndrome / Q000188:drug therapy; D012307:Risk Factors
D052160:Benzothiazoles; D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole; D010479:Pergolide; D000077487:Pramipexole